Harmony Biosciences announced preliminary Q2 2026 WAKIX sales of $261 million, a 30% YoY increase and a new record, leading to the reaffirmation of its full-year 2026 revenue guidance. The company also announced the departure of its CFO, Glenn Reicin, and the appointment of an interim CFO, Stephen Mollichella, which is presented as a non-disruptive transition.
Harmony Biosciences reported preliminary Q2 2026 WAKIX sales of $261 million, marking a 30% year-over-year increase and a new quarterly record. This strong performance led the company to reiterate its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, indicating continued confidence in its core product. The announcement of CFO Glenn Reicin's departure and the appointment of an interim CFO, Stephen Mollichella, is framed as a non-disruptive event, with the company emphasizing continuity. For traders, the strong sales figures and reaffirmed guidance present a positive short-term signal for HRMY, while the CFO transition, though downplayed, introduces a minor long-term uncertainty regarding financial leadership, though the company states it will not affect performance.